Drug firm Lupin on Monday received the approval from the United States (US) health regulator to market Levothyroxine Sodium tablets used for treatment of hypothyroidism.
The company has received an approval from the United States Food and Drug Administration (USFDA) to market the tablets in the strengths of 25 microgram (mcg), 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg, Lupin said.
The product is a generic version of AbbVie Inc’s Synthroid tablets in the same strengths, it added.
According to IQVIA MAT September 2018 data, Levothyroxine Sodium tablets had an annual sale of about $2.5 billion in the US market, Lupin said.
The tablets are indicated for hypothyroidism and as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer, it added.
Shares of Lupin closed at Rs 865.50 per scrip on the Bombay Stock Exchange (BSE), up 0.69 per cent from the previous close.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.